Orquest plans autumn IDE submission for Healos collagen-based bone grafting material.
This article was originally published in The Gray Sheet
ORQUEST HEALOS BONE GRAFTING MATERIAL ENTERS CLINICALS in Europe, the company says. Mountain View, California-based Orquest announced June 18 that it has commenced patient enrollment in a feasibility study evaluating use of the resorbable hydroxyapatite-coated collagen fiber material in spinal fusion procedures for patients with degenerative disc disease (DDD).
You may also be interested in...
AMAG outlines plans for retrospective real-world evidence studies, and possibly a new placebo-controlled trial with a primary endpoint of preterm birth <32 weeks, in a filing opposing the Center for Drug Evaluation and Research’s proposal to withdraw the drug.
The leading Korean pharma firm’s oral, third-generation EGFR-TKI is approved in the country, providing a new option for patients with advanced NSCLC and increasing hopes for global approvals given an ongoing global Phase III combination trial led by partner J&J.
DePuy Synthes expects its Velys robotic-assisted system to be cost-effective, easy-to-use and to be well-suited for use in ambulatory surgery centers.